Terms: = Leukemia AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Treatment
15 results:
1. Regulation of Cell Cycle Progression through RB Phosphorylation by Nilotinib and AT-9283 in Human Melanoma A375P Cells.
Pham TM; Ahmed M; Lai TH; Bahar ME; Hwang JS; Maulidi RF; Ngo QN; Kim DR
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474202
[TBL] [Abstract] [Full Text] [Related]
2. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
Daver NG; Vyas P; Kambhampati S; Al Malki MM; Larson RA; Asch AS; Mannis G; Chai-Ho W; Tanaka TN; Bradley TJ; Jeyakumar D; Wang ES; Sweet K; Kantarjian HM; Garcia-Manero G; Komrokji R; Xing G; Ramsingh G; Renard C; Zeidner JF; Sallman DA
J Clin Oncol; 2023 Nov; 41(31):4893-4904. PubMed ID: 37703506
[TBL] [Abstract] [Full Text] [Related]
3. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract] [Full Text] [Related]
4. Impact of pre-transplantation minimal residual disease (MRD) on the outcome of Allogeneic hematopoietic stem cell transplantation for acute leukemia.
Shen X; Pan J; Qi C; Feng Y; Wu H; Qian S; Lu H; Chen L; Li J; Miao K; Qiu H; Zhu H
Hematology; 2021 Dec; 26(1):295-300. PubMed ID: 33648437
[TBL] [Abstract] [Full Text] [Related]
5. The establishment and evaluation of a new model for the prediction of Children B-ALL based on TARGET: A SQUIRE-compliant study.
Gao X; Liu W
Medicine (Baltimore); 2020 May; 99(19):e20115. PubMed ID: 32384487
[TBL] [Abstract] [Full Text] [Related]
6. Boosting the apoptotic response of high-grade serous ovarian cancers with ccne1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract] [Full Text] [Related]
7. Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
Hassani S; Khaleghian A; Ahmadian S; Alizadeh S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Ann Hematol; 2018 Jan; 97(1):83-93. PubMed ID: 29159499
[TBL] [Abstract] [Full Text] [Related]
8. Financial Burden for Patients With Chronic Myeloid leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications.
Shen C; Zhao B; Liu L; Shih YT
J Oncol Pract; 2017 Feb; 13(2):e152-e162. PubMed ID: 28095170
[TBL] [Abstract] [Full Text] [Related]
9. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.
Sung AH; Marcella SW; Xie Y
J Med Econ; 2015 May; 18(5):341-8. PubMed ID: 25524741
[TBL] [Abstract] [Full Text] [Related]
10. Prevalence of being underweight and overweight and obesity at diagnosis in UK patients with childhood acute lymphoblastic leukaemia 1985-2002.
Aldhafiri FK; McColl JH; Reilly JJ
J Hum Nutr Diet; 2014 Feb; 27(1):76-9. PubMed ID: 23781853
[TBL] [Abstract] [Full Text] [Related]
11. Acute myeloid leukaemia in Western Australia 1991-2005: a retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome.
Gangatharan SA; Grove CS; P'ng S; O'Reilly J; Joske D; Leahy MF; Threlfall T; Wright MP
Intern Med J; 2013 Aug; 43(8):903-11. PubMed ID: 23611681
[TBL] [Abstract] [Full Text] [Related]
12. treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract] [Full Text] [Related]
13. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
[TBL] [Abstract] [Full Text] [Related]
14. Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
Schleyer E; Braess J; Ramsauer B; Unterhalt M; Kaufmann C; Wilde S; Schüssler M; Hiddemann W
Leukemia; 1995 Jun; 9(6):1085-90. PubMed ID: 7596174
[TBL] [Abstract] [Full Text] [Related]
15. Characterization of bcr gene products in hematopoietic cells.
Li WJ; Dreazen O; Kloetzer W; Gale RP; Arlinghaus RB
Oncogene; 1989 Feb; 4(2):127-38. PubMed ID: 2648252
[TBL] [Abstract] [Full Text] [Related]
